Review of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials

Basit Öğe Kaydı
dc.authorid0000-0001-9081-2405
dc.authorid0000-0001-9081-2405
dc.authorwosidseber, selcuk e/H-3327-2017
dc.authorwosidKorkmaz, Taner/W-8464-2018
dc.authorwosidseber, selcuk/T-9539-2019
dc.authorwosidBasaran, Gul Atalay/AAT-7780-2020
dc.contributor.authorKorkmaz, Taner
dc.contributor.authorSeber, Selçuk
dc.contributor.authorBaşaran, Gül
dc.date.accessioned2022-05-11T14:40:55Z
dc.date.available2022-05-11T14:40:55Z
dc.date.issued2016
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Radyasyon Onkolojisi Ana Bilim Dalı
dc.description.abstractLate and recurrent stage ovarian cancer has a high mortality and low response rate to therapy beyond first line treatment. Although first line platinum/taxane based regimens have a satisfactory response rate eventually in most cases disease recurrence is common and second-line treatments are not curative. Delaying progression or recurrence is the main goal of current ongoing clinical studies by means of establishing an effective maintenance regimen with acceptable toxicity profile. Clearly, the persistence of dormant and drug-resistant cells after front-line treatments results in the inability to cure the disease. Over the past several years, the idea of prolongation of therapy for ovarian cancer has garnered clinical attention and academic debate. As a result of a greater understanding of the molecular pathways involved in carcinogenesis and tumor growth, a large number of potential therapeutic targets have been identified and drugs to block receptors, ligands or pathways are being developed. Currently, numerous clinical trials with targeted agents have just been completed or are ongoing involving patients achieving a complete or durable response after first-line and beyond the first line chemotherapy in order to evaluate the efficacy of different therapeutic approaches in terms of progression-free survival and overall survival. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
dc.identifier.doi10.1016/j.critrevonc.2015.10.006
dc.identifier.endpage188
dc.identifier.issn1040-8428
dc.identifier.issn1879-0461
dc.identifier.pmid26603345
dc.identifier.startpage180
dc.identifier.urihttps://doi.org/10.1016/j.critrevonc.2015.10.006
dc.identifier.urihttps://hdl.handle.net/20.500.11776/8975
dc.identifier.volume98
dc.identifier.wosWOS:000370086400018
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.institutionauthorSeber, Selçuk
dc.language.isoen
dc.publisherElsevier Science Inc
dc.relation.ispartofCritical Reviews in Oncology Hematology
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectOvarian cancer
dc.subjectMaintenance treatment
dc.subjectTargeted therapy
dc.subjectRandomized Phase-Iii
dc.subjectPegylated Liposomal Doxorubicin
dc.subjectEndothelial Growth-Factor
dc.subjectPrimary Peritoneal
dc.subjectFallopian-Tube
dc.subjectPlatinum
dc.subjectChemotherapy
dc.subjectBevacizumab
dc.subjectCarcinoma
dc.subjectOlaparib
dc.titleReview of the current role of targeted therapies as maintenance therapies in first and second line treatment of epithelial ovarian cancer; in the light of completed trials
dc.typeReview Article

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
8975.pdf
Boyut:
665.12 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Tıp Fakültesi Koleksiyonu